research A Review of Coumarin Derivatives in Pharmacotherapy of Breast Cancer
Coumarin derivatives show promise as anti-estrogenic agents for treating breast cancer, with some in clinical trials.
Search
for
Sort by
Research
60-90 / 1000+ results 
research Effect of estrogens on skin aging and the potential role of selective estrogen receptor modulators
Estrogens and SERMs can help with skin aging, but their safety and effectiveness need more research.
research Women's midlife health Reframing menopause
The document concludes that menopause should be seen as a natural part of aging and managed with personalized care and informed choices.
research Antiaging effects of equol: A unique antiandrogenic isoflavone metabolite and its influence in stimulating collagen deposition in human dermal monolayer fibroblasts
Equol may help with antiaging and skin health by boosting collagen and blocking certain hormones.
research Combinatorial Therapy of Letrozole- and Quercetin-Loaded Spanlastics for Enhanced Cytotoxicity against MCF-7 Breast Cancer Cells
Combining letrozole and quercetin in spanlastics may improve breast cancer treatment.
research Female pattern hair loss possibly caused by tamoxifen: Androgen receptor expression in the outer root sheath in the affected area
Tamoxifen may cause female hair loss by increasing androgen receptor expression.
research Tamoxifen-Induced Female Androgenetic Alopecia in a Patient with Breast Cancer
Tamoxifen caused hair loss in a 52-year-old woman.
research FCE 28260, a new 5α-reductase inhibitor: In vitro and in vivo effects
FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.
research Risk of Estrogen-Driven Malignancies in Females on 5-alpha Reductase Inhibitors
Using 5-alpha reductase inhibitors may lower the risk of breast cancer in females.
research Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial
Long-term treatment with palbociclib plus letrozole maintains quality of life in certain breast cancer patients.
research Off-label prescriptions: patient safety first
Off-label drug use can be risky and requires careful consideration to ensure patient safety.
research 5α-Reductase inhibitors in androgenetic alopecia
research Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases
Finasteride has a higher risk of reproductive side effects than minoxidil.
research Optimizing finasteride chemoprevention
research Dual-drug nanostructured lipid carriers of spironolactone and 2-deoxy-D-ribose for targeted follicular delivery in androgenetic alopecia
Nanocarriers with spironolactone and 2-deoxy-D-ribose may improve hair loss treatment by targeting hair follicles directly.
research Finasteride blocks progesterone synthesis in MA-10 Leydig tumor cells
research Ritlecitinib: First Approval
Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
research Adverse effects with finasteride 5 mg/day for patterned hair loss in premenopausal women
Taking 5 mg/day finasteride can cause side effects in women with hair loss, but these are usually mild and fade over time, making the treatment beneficial in the long run.
research Identification of xenobiotics interfering with 5 α -reductase (SRD5A2) activity
MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.
research Abstract P5-09-21: Selective androgen receptor modulators (SARMs): Enobosarm as targeted therapy for the treatment of androgen receptor-positive breast cancer
Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
research Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men
research Finasteride and Its Potential for the Treatment of Female Pattern Hair Loss: Evidence to Date
Finasteride may help treat female hair loss, but has risks.
research Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.
research Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study
Oral 5-alpha reductase inhibitors do not increase breast cancer or benign breast disorder risk in women.
research Kinetic analysis of LY320236: competitive inhibitor of type I and non-competitive inhibitor of type II human steroid 5α-reductase
LY320236 is a strong blocker of two enzymes that change testosterone into dihydrotestosterone and might help treat conditions related to male hormones.
research Association of 5-α reductase inhibitors and sexual dysfunction: A RADAR report
Using hair loss drugs finasteride and dutasteride may cause sexual side effects.
research Proxalutamide (GT0918) Reduces the Rate of Hospitalization in mild-to-moderate COVID-19 Female Patients: A Randomized Double-Blinded Placebo-Controlled Two-Arm Parallel Trial
Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.
research Bicalutamide and the new perspectives for female pattern hair loss treatment: What dermatologists should know
Bicalutamide, a drug with a good safety profile, is a promising new treatment for female pattern hair loss.
research Gonadotropin-Releasing Hormone Agonist Treatment in Postmenopausal Women with Hyperandrogenism of Ovarian Origin
Treatment with a hormone agonist can reduce excess male hormones in postmenopausal women without surgery.
research 61537 No Increased Risk of Breast or Gynecologic Cancers in Women with 5α-Reductase Inhibitor Exposure for Female Pattern Hair Loss: A Population-Based Propensity Score-Matched Cohort Study
Using 5α-reductase inhibitors for hair loss in women doesn't increase cancer risk.